Business
Placing and Subscription to raise approx £1.4m
Fusion Antibodies plc has successfully raised approximately £1.4 million before expenses through a placing and subscription of 11,056,905 new ordinary shares at 13 pence per share. This capital raise, which includes a £19,861.92 subscription by Non-Executive Director Colin Walsh, will be used to accelerate the commercialisation of its OptiMAL® platform, invest in strategic partnerships, fund global marketing efforts, and strengthen proprietary technologies. The company also announced the proposed issuance of 308,720 new ordinary shares to certain executive directors in satisfaction of a portion of their bonuses. Admission of the new shares to trading on AIM is anticipated on January 30, 2026. Disclaimer*
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n\nTHIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN, NEW ZEALAND OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.\n \nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED (\"EUWA\")) (\"UK MAR\"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n \n27 January 2026\n \nFusion Antibodies plc\n(\"Fusion\" or the \"Company\")\n \nPlacing and Subscription to raise approximately £1.4 million\n \nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has conditionally raised approximately £1.4 million (before expenses) through the issue of 11,056,905 new ordinary shares of 4 pence each in the Company (\"Ordinary Shares\") at a price of 13 pence per new Ordinary Share (the \"Issue Price\"), as follows:\n \n· approximately £1.4 million (before expenses) has been raised by way of a placing of a total of 10,904,121 new Ordinary Shares (the \"Placing Shares\") at the Issue Price with new investors and existing shareholders (the \"Placing\"); and\n \n· Colin Walsh, Non-Executive Director, has directly subscribed with the Company for 152,784 new Ordinary Shares (the \"Subscription Shares\") at the Issue Price (the \"Subscription\", and together with the Placing, the \"Fundraise\"), raising £19,861.92 (before expenses).\n \nAllenby Capital Limited (\"Allenby Capital\") and Shard Capit...